CLINICAL_TRIALS
trial_result
· 2021-10-27
Clinical Trial Update: Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD [Phase 2]
Summary
Phase 2 trial updates on SPN-812 (viloxazine ER) for ADHD in children show efficacy and safety data.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 | Status: COMPLETED | Results posted: 2021-10-27